Page 1

August 16 , 2021 Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates Strategic Highlights ■ Received an issued US Patent titled " High Throughput Optical Assay of Human Mixed Cell Population Spheroids " by the United States Patent and Trademark Office ( USPTO ) . The patent covers the use of spheroids and organoids for drug discovery . ■ Entered into a strategic collaboration with Ordaōs Bio and Cellaria , Inc. to execute an integrated model for rapid iteration of therapeutic design using artificial intelligence ( " AI " ) and human - derived in vitro ' avatar clinical trials ' to enable the design , development , and testing of potential therapeutics on targeted patient populations , during preclinical discovery with a primary focus in oncology . ■ Completed a large primary screening of Al - generated novel compounds for Rett Syndrome yielding promising results , including a first round of hit expansion screening across two novel targets . ■ Elevated our syngeneic bladder instillation model into toxicology screening , which will be performed in vivoPharm's animal models . ▪ Progressed internal programs that apply Vyant Bio's expertise with human - derived cell based organoids to explore neurodegenerative disorders , including Parkinson's and Alzheimer's disease . ■ Commenced the development of Al - based molecule and biologic creation for in - vitro testing through in - silico structure - function prediction . ■ Cash position at June 30 , 2021 was $ 26.5 million . CHERRY HILL , N.J. , Aug. 16 , 2021 ( GLOBE NEWSWIRE ) -- Vyant Bio , Inc. ( " Vyant Bio " , " Company " ) ( Nasdaq : VYNT ) , an emerging global drug discovery company , is rapidly identifying small and large molecule therapeutics to treat central nervous system ( CNS ) and oncology - related diseases . Today , Vyant Bio reports its Second Quarter 2021 strategic and business updates in a conference call scheduled for 4:30 p.m. ET . " We have achieved a tremendous amount of momentum in the first 90 days since launching the Vyant Bio brand and completing the merger we announced at the end of March 2021 . Vyant Bio is committed to transforming the way drugs are discovered by quickly adapting to exciting new technologies and combining capabilities in ways that leverage their strengths , " stated Jay Roberts , CEO of Vyant Bio . " Our internal teams of scientists , data scientists and engineers , coupled with the capabilities of select strategic partners that are now integrated into our platform , allow us all to work together to design and develop superior therapeutics and position us to build a robust pipeline of novel therapeutics targeting degenerative and developmental neurological disorders and cancers with high unmet needs . " Vyant Bio's drug discovery platform uses both human - induced pluripotent stem cell - derived ( hiPSC ) and primary human cell organoids as proprietary disease models combined with